PTPRD Phosphatase Inhibitors for Stimulant Use Disorders

Grants and Contracts Details


Statement of Work The investigators at the University of Kentucky will assist in the advancement of a novel, well tolerated and orally bioavailable PTPRD phosphatase inhibitor with in vitro potency, intellectual property protection, selectivity and stability to use in humans while advancing toward subsequent human testing in longer studies with stimulant drugs. Key biological and/or chemical resources will be regularly authenticated to ensure their identity and validity for use in the proposed studies.
Effective start/end date7/1/226/30/23


  • University of Maryland at Baltimore: $38,250.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.